Abstract
One of the most characteristic features of multiple myeloma is the development of osteolytic bone lesions. Myeloma-associated bone disease is caused by an increase in osteoclastic bone resorption and a decrease in osteoblastic new bone formation. Insight into the molecular mechanisms of osteoclastogenesis has been provided by the detection of receptor activator of NF-kB ligand (RANKL), its specific receptor (RANK) and its decoy receptor antagonist osteoprotegerin (OPG). The RANK signaling system is abnormally regulated in multiple myeloma and targeting this system may ameliorate myeloma bone disease. Less is known about the development of osteoblastic dysfunction, and further knowledge about the interaction between myeloma cells and osteoblasts is required. The aim of this review is to focus on the principles of bone biology for a better understanding of the development of myeloma bone disease and to identify possible therapeutic targets.
Keywords: multiple myeloma, osteoblasts, osteoclasts, rank signaling system
Current Drug Targets
Title: Identification of New Targets for Therapy of Osteolytic Bone Disease in Multiple Myeloma
Volume: 6 Issue: 6
Author(s): O. Hjertner, T. Standal, M. Borset, A. Sundan and A. Waage
Affiliation:
Keywords: multiple myeloma, osteoblasts, osteoclasts, rank signaling system
Abstract: One of the most characteristic features of multiple myeloma is the development of osteolytic bone lesions. Myeloma-associated bone disease is caused by an increase in osteoclastic bone resorption and a decrease in osteoblastic new bone formation. Insight into the molecular mechanisms of osteoclastogenesis has been provided by the detection of receptor activator of NF-kB ligand (RANKL), its specific receptor (RANK) and its decoy receptor antagonist osteoprotegerin (OPG). The RANK signaling system is abnormally regulated in multiple myeloma and targeting this system may ameliorate myeloma bone disease. Less is known about the development of osteoblastic dysfunction, and further knowledge about the interaction between myeloma cells and osteoblasts is required. The aim of this review is to focus on the principles of bone biology for a better understanding of the development of myeloma bone disease and to identify possible therapeutic targets.
Export Options
About this article
Cite this article as:
Hjertner O., Standal T., Borset M., Sundan A. and Waage A., Identification of New Targets for Therapy of Osteolytic Bone Disease in Multiple Myeloma, Current Drug Targets 2005; 6 (6) . https://dx.doi.org/10.2174/1389450054863716
DOI https://dx.doi.org/10.2174/1389450054863716 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
The Role of EGCG in Breast Cancer Prevention and Therapy.
Mini-Reviews in Medicinal Chemistry Editorial
Current Molecular Medicine Mechanism and Inhibition of Matrix Metalloproteinases
Current Medicinal Chemistry Quantum Dot-Based Nanoprobes for In Vivo Targeted Imaging
Current Molecular Medicine Development of Thieno[3`,2`:5,6]thiopyrano[4,3-c]pyrazole-3-carboxamide Derivatives as the Estrogen Receptor Ligands: Synthesis, Characterization and Biological Activity
Medicinal Chemistry Intraperitoneal Chemotherapy as Primary Treatment of Advanced Ovarian Cancer:Efficacy, Toxicity, and Future Directions
Reviews on Recent Clinical Trials Sodium Dependent Multivitamin Transporter (SMVT): A Potential Target for Drug Delivery
Current Drug Targets The Small Bowel: An Imaging Guide
Current Medical Imaging Oxidative Stress and its Clinical Consequences: Relationship between Diabetes and Cancer
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Synthesis of Novel Thieno[2,3-d]pyrimidine Derivatives and Evaluation of Their Cytotoxicity and EGFR Inhibitory Activity
Anti-Cancer Agents in Medicinal Chemistry A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Blood-Brain Barrier Transport of Drugs for the Treatment of Brain Diseases
CNS & Neurological Disorders - Drug Targets Clinical Evaluation of Natural History of Peyronie’s Disease: Our Experience, Old Myths and New Certainties
Inflammation & Allergy - Drug Targets (Discontinued) Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Rasburicase: A New Approach for Preventing and/or Treating Tumor Lysis Syndrome
Current Pharmaceutical Design The Significance of Meat in the Diet
Current Nutrition & Food Science The Role of Neuronal Insulin/Insulin-Like Growth Factor-1 Signaling for the Pathogenesis of Alzheimer’s Disease: Possible Therapeutic Implications
CNS & Neurological Disorders - Drug Targets Synthesis and Evaluation of a New Series of Arylidene Indanones as Potential Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Fused Xanthone Derivatives as Antiproliferative Agents
Anti-Cancer Agents in Medicinal Chemistry Radiotherapy for Non-Melanoma Skin Cancer
Current Cancer Therapy Reviews